These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 27807652)
1. Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Denda T; Kanda M; Morita Y; Kim HM; Kashiwada T; Matsuda C; Fujieda S; Nakata K; Murotani K; Oba K; Sakamoto J; Mishima H Cancer Chemother Pharmacol; 2016 Dec; 78(6):1253-1261. PubMed ID: 27807652 [TBL] [Abstract][Full Text] [Related]
2. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157 [TBL] [Abstract][Full Text] [Related]
3. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364 [TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155 [TBL] [Abstract][Full Text] [Related]
5. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845 [TBL] [Abstract][Full Text] [Related]
6. Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study. Tezuka T; Hamada C; Ishida H; Ooshiro M; Matsuoka H; Kawasaki S; Mishima H; Maeda K; Sakamoto J; Koda K Invest New Drugs; 2013 Oct; 31(5):1321-9. PubMed ID: 23817973 [TBL] [Abstract][Full Text] [Related]
7. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. Gamelin E; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M J Clin Oncol; 2008 May; 26(13):2099-105. PubMed ID: 18445839 [TBL] [Abstract][Full Text] [Related]
8. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604 [TBL] [Abstract][Full Text] [Related]
10. The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). Bendell JC; Sauri T; Gracián AC; Alvarez R; López-López C; García-Alfonso P; Hussein M; Miron ML; Cervantes A; Montagut C; Vivas CS; Bessudo A; Plezia P; Moons V; Andel J; Bennouna J; van der Westhuizen A; Samuel L; Rossomanno S; Boetsch C; Lahr A; Franjkovic I; Heil F; Lechner K; Krieter O; Hurwitz H; Oncologist; 2020 Mar; 25(3):e451-e459. PubMed ID: 32162804 [TBL] [Abstract][Full Text] [Related]
11. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Kabbinavar F; Hurwitz HI; Fehrenbacher L; Meropol NJ; Novotny WF; Lieberman G; Griffing S; Bergsland E J Clin Oncol; 2003 Jan; 21(1):60-5. PubMed ID: 12506171 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802). Ohta T; Kato T; Kawakami H; Miyake Y; Goto M; Iwamoto S; Otsuji T; Nakamura M; Sugimoto N; Okamura S; Kotaka M; Tsujie M; Tokunaga Y; Mishima H; Hata T; Shimokawa T; Kurokawa Y; Satoh T Int J Clin Oncol; 2020 Jul; 25(7):1291-1298. PubMed ID: 32219630 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer. Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316 [TBL] [Abstract][Full Text] [Related]
14. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775 [TBL] [Abstract][Full Text] [Related]
15. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. Van Cutsem E; Prenen H; D'Haens G; Bennouna J; Carrato A; Ducreux M; Bouché O; Sobrero A; Latini L; Staines H; Oum'Hamed Z; Dressler H; Studeny M; Capdevila J Ann Oncol; 2015 Oct; 26(10):2085-91. PubMed ID: 26272806 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. Kuramochi H; Ando M; Itabashi M; Nakajima G; Kawakami K; Hamano M; Hirai E; Yokomizo H; Okuyama R; Araida T; Yoshimatsu K; Kameoka S; Hayashi K Cancer Chemother Pharmacol; 2017 Mar; 79(3):579-585. PubMed ID: 28213683 [TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). Suenaga M; Nishina T; Mizunuma N; Yasui H; Ura T; Denda T; Ikeda J; Esaki T; Nishisaki H; Takano Y; Sugiyama Y; Muro K BMC Cancer; 2015 Mar; 15():176. PubMed ID: 25884814 [TBL] [Abstract][Full Text] [Related]
18. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer]. Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326 [TBL] [Abstract][Full Text] [Related]
19. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138 [TBL] [Abstract][Full Text] [Related]
20. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]